Skip to main content
. 2019 Jul 26;121(5):429–430. doi: 10.1038/s41416-019-0528-0

Fig. 1.

Fig. 1

a Progression-free survival at final analysis and b overall survival at final analysis. CI confidence interval, PBO placebo + FOLFIRI ± bevacizumab, VEL veliparib + FOLFIRI ± bevacizumab